# Does Caffeine Reduce Dipyridamole-Induced Protection Against Ischemia-Reperfusion Injury?

> **NCT00430170** · PHASE4 · COMPLETED · sponsor: **Radboud University Medical Center** · enrollment: 20 (actual)

## Conditions studied

- Cardiovascular Disease
- Ischemia-Reperfusion Injury

## Interventions

- **DRUG:** Dipyridamole
- **DRUG:** caffeine

## Key facts

- **NCT ID:** NCT00430170
- **Lead sponsor:** Radboud University Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-01
- **Primary completion:** 2007-03
- **Final completion:** 2007-04
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2008-07-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00430170

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00430170, "Does Caffeine Reduce Dipyridamole-Induced Protection Against Ischemia-Reperfusion Injury?". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT00430170. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*